Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation
NCT00141726Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2003
- Primary completion
- Jul 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in not applicable; "lung injury" is not a specific disease, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Percent of Patients With a Greater Than or Equal to 10% Improvement in FEV1, or FVC, and DLCO at 12 weeks. Started Oct 2003; status: completed.
02
Drugs
etanercept
03
Conditions
not applicable; "lung injury" is not a specific disease
Beyond the preview
Go deeper on NCT00141726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141726.